New Brain Network Discovery Redefines Understanding of Parkinson’s Disease

Parkinson’s disease, a progressive neurological disorder affecting over 1 million individuals in the United States and more than 10 million worldwide, has long been characterized by motor symptoms like tremors and movement difficulties. However, emerging research suggests the disease’s roots lie deeper, within a complex brain network responsible for integrating cognition and action. A new international study has pinpointed this network, called the somato-cognitive action network (SCAN), offering a potential paradigm shift in treatment strategies.

Beyond Movement: The Broad Spectrum of Parkinson’s Symptoms

While traditionally viewed as a movement disorder, Parkinson’s disease manifests with a diverse range of symptoms extending beyond motor control. These include sleep disturbances, digestive issues, cognitive impairments, and even changes in motivation. This broad symptom profile has puzzled researchers, prompting a search for a unifying neurological explanation.

Introducing the SCAN: A Key Brain Network

The SCAN, first described in 2023, resides within the motor cortex – the brain region governing movement. It’s responsible for translating intentions into actions and processing feedback during movement execution. Researchers now believe dysfunction within the SCAN is a central feature of Parkinson’s disease. According to Nico U. Dosenbach, MD, PhD, professor of neurology at Washington University in St. Louis, “This work demonstrates that Parkinson’s is a SCAN disorder, and the data strongly suggest that if you target the SCAN in a personalized, precise manner you can treat Parkinson’s more successfully than was previously possible.”¹

Hyperconnectivity and the Root of the Problem

Analysis of brain imaging data from over 800 participants – including those with Parkinson’s disease undergoing deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), focused ultrasound stimulation, or medication, as well as healthy controls – revealed a key characteristic of Parkinson’s: hyperconnectivity between the SCAN and the subcortex. The subcortex plays a crucial role in emotion, memory, and motor control. This abnormal wiring disrupts the normal flow of information, impacting not only movement but also cognitive and bodily functions.¹

Targeting the SCAN with TMS: Promising Results

The study explored the potential of targeting the SCAN with transcranial magnetic stimulation (TMS), a non-invasive brain stimulation technique. Results showed that SCAN-targeted TMS more than doubled the improvement in symptoms compared to TMS applied to surrounding brain areas. In a clinical trial, 56% of patients receiving SCAN-targeted TMS showed a positive response after two weeks, compared to just 22% in the control group. ¹

The Future of Parkinson’s Treatment

These findings suggest a new approach to Parkinson’s treatment, focusing on restoring normal activity within the SCAN. Researchers are optimistic that this precision-based approach could slow or even reverse disease progression, rather than simply managing symptoms. Dosenbach notes that non-invasive treatments like TMS could allow for earlier intervention than DBS, which requires brain surgery.¹

Further research is underway, including clinical trials utilizing surface electrode strips and low-intensity focused ultrasound to modulate SCAN activity and address specific symptoms like gait dysfunction.¹ This discovery marks a significant step forward in understanding and treating Parkinson’s disease, offering hope for more effective therapies in the future.

Key Takeaways

• Parkinson’s disease is increasingly understood as a disorder of a specific brain network – the somato-cognitive action network (SCAN).
• Dysfunction within the SCAN, characterized by hyperconnectivity with the subcortex, appears to underlie the diverse symptoms of Parkinson’s.
• Targeting the SCAN with non-invasive brain stimulation techniques like TMS shows promise for improving symptoms and potentially slowing disease progression.
• Future research is focused on refining SCAN-targeted therapies and exploring their potential to address specific Parkinson’s symptoms.

Source: Washington University in St. Louis¹